[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-fog\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-fog":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,82,107,132,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100633163","mecfs-brain-fog-cognitive-rehabilitation-trial-100633163",false,"NCT07523113","ME\u002FCFS Brain Fog: Cognitive Rehabilitation Trial","Brain Training for Chronic, Post-viral, Brain Fog: Study A","Inclusion Criteria:\n\n* diagnosis of ME\u002FCFS that preceded cognitive complaints\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* some impairment in the performance of daily activities\n* ≥ 18 years, no upper limit if medically stable\n* reside in the community (as opposed to a hospital or skilled nursing facility)\n* able to travel to the laboratory on multiple occasions\n* has Internet service\n* has a personal computer, laptop, or tablet that can access the Internet\n* sufficiently fit, from both a physical and mental health perspective, to take part in the study\n* adequate sight and hearing to complete the UFOV test\n* adequate thinking skills, e.g., ability to follow directions and retain information to complete UFOV and CTAL, as marked by the judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL\n* sufficient English proficiency (i.e., ability to speak, understand, read, and write to take part in study activities)\n\nExclusion Criteria:\n\n* cognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse, or due to another type of brain injury, such as traumatic brain injury, stroke, or a progressive brain disease, such as Alzheimer's Dementia\n* current substance abuse disorder\n* diagnosis of postural orthostatic tachycardia syndrome (POTS) by a healthcare provider\n* prior cognitive processing speed training on DoubleDecision or a similar program\n* cannot tolerate taVNS\n* prior history of heart attack or other serious cardiac events\n* implanted medical device of any type\n* vasovagal syncope or history of fainting\n* history of seizures or epilepsy\n* temporomandibular Joint (TMJ) syndrome or other conditions that cause substantial jaw pain\n* history of peripheral nerve injury to the head, neck, or face\n* pregnant or breastfeeding\n* not able or willing to get an MRI scan\n* not able or willing to get a blood draw","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to compare two approaches to cognitive rehabilitation in adults with post-viral cognitive syndrome, which resulted in brain fog. All participants will be screened for eligibility prior to participation. Most of the procedures will take place over a phone call or secure telehealth platform (i.e., Zoom). However, participants will be asked to visit UAB on three occasions for blood sample collection and brain imaging (about 2 hours each). Online testing will happen one month before treatment, one day before treatment, one day afterwards, and 6 months afterwards. The study will utilize two different forms of rehabilitation training to improve participants' cognitive ability. Participants will be randomized to one of the two treatment groups. The first treatment approach, known as Constraint-Induced Cognitive Therapy (CICT), will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) online training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation, also known as trans-auricular VNS (taVNS). The second approach, known as Brain Fitness Training (BFT), will include (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, breathing, healthy nutrition, and healthy sleep, (C) education about how relaxation, breathing, nutrition, and sleep are connected to thinking effectiveness, and (D) taVNS. Approximately 30 hours of training will be conducted over a secure telehealth platform (i.e., Zoom) in the span of two- to four- weeks. A typical CICT session will consist of one hour of gaming, with the bulk of the session being spent on cognitive training of the target behaviors and procedures designed to promote transfer of therapeutic gains to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. A typical BFT session will consist of one hour of gaming, training on healthy lifestyle behaviors (i.e., healthy sleep, nutrition, and relaxation habits), as well as procedures designed to promote transfer of behavior changes to daily life. Ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. Training sessions in both conditions will be scheduled based on participants' availability, with the options for sessions scheduled to be as close as every weekday over 2 weeks or as loosely as every other weekday (i.e., over a 4-week span). If a caregiver is available, they will receive training on how to best support participants in their therapeutic program. After the training ends, both groups will receive 4 follow-up phone calls approximately one week apart to promote integration of the gained skills into everyday life. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life.",[26,27,28,29,30,31,32,33],"ME\u002FCFS","ME\u002FCFS Following EBV-associated Infectious Mononucleosis","ME\u002FCFS Following COVID-19","Chronic Fatigue","Chronic Fatigue Syndrome (CFS)","Brain Fog","Cognitive Impairment","Cognitive Dysfunction",[26,29,35,32,33,36,37,38],"Brain fog","post-viral syndrome","Cognitive Rehabilitation","CICT","RECRUITING","2026-08-12",{"date":42,"type":43},"2026-08-14","ACTUAL",{"date":45,"type":43},"2026-06-23",{"date":47,"type":20},"2028-06",{"name":49,"class":50},"University of Alabama at Birmingham","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100648412","a-clinical-trial-to-evaluate-the-effects-of-the-edgeease-pmam-system-on-mood-mental-clarity-sleep-quality-and-digestive-wellbeing-100648412","NCT07721506","A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing","Inclusion Criteria:\n\n* Male and female adults aged 18 to 65 years.\n* Self-reports difficulty falling asleep, staying asleep, or having poor sleep quality overall, in the last 4 weeks.\n* Self-reports seeking support in at least one of the following domains: Difficulty switching off, perceived stress load, mental overload, next-day mental fatigue, reduced mental clarity or reduced cognitive readiness.\n* Generally healthy.\n* Willing and able to take the PM product (one serving mixed in water) in the evening and the AM product (two capsules with food) in the morning daily for 12 weeks.\n* Willing to maintain current diet, exercise, caffeine, alcohol, and sleep routines for the duration of the study.\n* Willing to wear a Fitbit continuously during the trial, and for 7 days prior to starting the test product.\n* Resides in the United States.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any ingredient in the test product.\n* Currently pregnant, breastfeeding, or trying to conceive, or will be during the study period.\n* Currently undergoing treatment for cancer, or have had a serious illness requiring hospitalization in the last 3 months.\n* Diagnosed severe psychiatric disorder (e.g., bipolar disorder, schizophrenia, major depressive disorder requiring active treatment adjustment) that, in the judgment of the Investigator, would compromise participation or interpretation of results.\n* Diagnosed inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), celiac disease, or other significant gastrointestinal condition requiring active management.\n* Current use of prescription antidepressants\u002Fanxiolytics, or other prescription neurologically-active medications that have been initiated or had a dose change within the past 90 days.\n* Current use of prescription sleep medications.\n* Regular use (i.e. more than once per week) of melatonin, sedating antihistamines, CBD\u002FTHC used for sleep, valerian, ashwagandha, or other sleep-targeted supplements.\n* Initiation of a new dietary supplement targeted at sleep, mood, cognition, or digestion within the 30 days prior to enrollment, or planning to start such a supplement during the study.\n* Heavy drinkers, defined as more than 8 alcoholic drinks per week for women and more than 15 alcoholic drinks per week for men.\n* Currently taking thyroid medication.\n* Currently testing, or plan to in the next 12 weeks, a product for another research study.",true,"65 Years",{"count":61,"type":20},35,[23],"This is a decentralized, single-arm, open-label clinical trial evaluating the effects of the Edge+Ease PM+AM dietary supplement system on sleep quality, mood, mental clarity, focus, and digestive comfort in 35 generally healthy adults aged 18-65 years over 12 weeks of daily use.\n\nParticipants will take the Edge+Ease PM product (one serving of powder mixed in approximately 150-250 mL water) in the evening approximately 60-90 minutes before bedtime, and the Edge+Ease AM product (two capsules) in the morning with food. All study activities are conducted remotely via the Citruslabs platform. Participants will complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and will wear a Fitbit continuously beginning 7 days before product use through the end of the 12-week intervention period to provide objective sleep data.",[65,66,67,31,68,69,70],"Sleep Quality","Mood","Mental Clarity","Digestive Comfort","Focus","Evening Wind-Down","NOT_YET_RECRUITING","2026-07-18",{"date":74,"type":43},"2026-07-23",{"date":76,"type":20},"2026-08",{"date":78,"type":20},"2026-12",{"name":80,"class":81},"Edge+Ease","INDUSTRY",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":51},"100523408","long-covid-brain-fog-cognitive-rehabilitation-trial-100523408","NCT06095297","Long COVID Brain Fog: Cognitive Rehabilitation Trial","Technique to Enable Return-to-Work by Employees With Long COVID Brain Fog","Inclusion Criteria:\n\n* \\>3 months post COVID\n* mild or greater cognitive impairment\n* moderate or greater brain fog\n* impairment in performance of daily activities\n* reside in community\n* reliable transportation to lab\n* sufficiently mentally and physically fit\n* adequate sight and hearing\n* ability to follow directions, and retain information\n* sufficient English proficiency\n\nExclusion Criteria:\n\n* cognitive impairment due to developmental disability, psychiatric disorder, or substance abuse, TBI or progressive brain disease\n* stroke prior to the onset of COVID\n* current substance abuse disorder\n* prior cognitive processing speed training on DoubleDecision or similar program\n* cannot tolerate trans-auricular vagus nerve stimulation",{"count":19,"type":20},[23],"This study will compare two approaches to cognitive rehabilitation in adults with long COVID with persistent, mild to moderate, cognitive impairment. One approach will feature (A) web-based computer \"games\" that trains how quickly individuals process information that they receive through their senses; (B) in-lab training on everyday activities with important cognitive components, (C) procedures designed to transfer improvements in cognition from the treatment setting to everyday life, and (D) a non-invasive form of vagus nerve stimulation (VNS), i.e., trans-auricular VNS (taVNS). Component B will include work-related tasks. This approach is termed Constraint-Induced Cognitive Therapy (CICT). The other approach will feature (A) web-based computer \"games\" that train reaction time and eye-hand coordination; (B) in-lab training on relaxation, healthy nutrition, and healthy sleep, (C) procedures designed to promote integration of these lifestyle changes into everyday life, and (D) taVNS. This approach is termed Brain Fitness Training (BFT).\n\nA subset of participants, who qualify for and and desire vocational rehabilitation (VR), will receive VR from the Alabama Department of Rehabilitation Services (ADRS) in addition to CICT or BFT. ADRS VR will include career counseling, prescription of on-the-job accommodations, and guidance on return-to-work. Those in the CICT + VR group will also receive on-the-job coaching from a peer mentor for a month after completing training.\n\nCICT, with or without VR, will involve 30 hours of training. Ten 3-hour in-lab, face-to-face, therapist-directed sessions will be scheduled. These sessions will feature one hour of gaming; the remainder will be committed to in-lab training on the target behaviors and the procedures designed to promote transfer of therapeutic gains to daily life and improving skills essential to work; the set of the latter procedures is termed the Transfer Package. ta-VNS will administered for 10 minutes before gaming and in-lab target behavior training. To accommodate the demands of participants' other activities, training sessions will be permitted to be scheduled as tightly as every weekday over 2 weeks or as loosely as every other weekday or so over 4 weeks. If a family caregiver is available, they will receive training on how to best support participants in their therapeutic program. After training ends, four follow-up phone calls will be scheduled approximately one-week apart with participants to promote integration of the skills gained during training into everyday life.\n\nBFT, with or without VR, will involve 30 hours of training following the same schedule as for CICT. Ten 3-hour in-lab, face-to-face, therapist-directed sessions will be scheduled. These sessions will feature one hour of gaming; the remainder will be committed to in-lab training on the target behaviors (healthy sleep, nutrition and relaxation habits) and the procedures designed to promote transfer of behavior change to daily life. ta-VNS will be administered for 10 minutes before gaming and in-lab target behavior training. If a family caregiver is available, they will receive training on how to best support participants in their therapeutic program. After training ends, four follow-up phone calls will be scheduled approximately one-week apart with participants to promote integration of the skills gained during training into everyday life.\n\nParticipants will be randomly assigned to the interventions. Randomization will be stratified by whether participants qualify for and desire VR from ADRS or not. If yes, participants will be randomized in equal numbers to CICT + VR or BFT + VR. If no, participants will be randomized in equal numbers to CICT or BFT.\n\nTesting will happen one month before treatment, one day before treatment, one day afterwards, and 6-months afterwards. Outcomes measured will include cognitive processing speed, cognitive function on laboratory tests, and spontaneous performance of everyday activities with important cognitive components in daily life. Another important outcome measure will be whether or not participants were able to return back to work or had significant improvements in their work activities.",[93,31,32,33,94],"Long COVID","Post-Acute COVID-19 Syndrome",[93,31,32,96,97,98,37],"Vocational Rehabilitation","COVID-19","PASC","2026-04-06",{"date":101,"type":43},"2026-04-13",{"date":103,"type":43},"2024-04-25",{"date":105,"type":20},"2027-12",{"name":49,"class":50},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":51},"100622191","a-study-to-evaluate-the-effects-of-a-supplement-on-the-side-effects-associated-with-stimulant-medications-100622191","NCT07380412","A Study to Evaluate the Effects of a Supplement on the Side Effects Associated With Stimulant Medications","Inclusion Criteria:\n\n* Aged 18-55 years\n* Currently prescribed stimulant medication for ADHD\n* Experiencing: sleep difficulty, irritability, anxiety, brain fog\n* Stable medication dose ≥3 months\n* Healthy with no uncontrolled chronic conditions\n* Stable on supplements ≥3 months if applicable\n* US resident\n* Willing to maintain current habits\n\nExclusion Criteria:\n\n* Chronic conditions (e.g. cancer, mental illness)\n* Use of psychiatric medications besides stimulants\n* Pregnancy, breastfeeding, thyroid, liver, kidney conditions\n* Recent smokers or heavy alcohol use\n* Night shift workers\n* Participation in other clinical trials\n* Allergies to product ingredients","55 Years",{"count":115,"type":20},90,[23],"This is a hybrid, two-arm, triple-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of the Stasis supplement on reducing oxidative stress, cortisol levels, and side effects associated with stimulant medications used for ADHD over a three-month period in adults.",[119,120,31],"ADHD","Sleep Disturbance",[119,122],"Anxiety","2026-01-28",{"date":125,"type":43},"2026-02-02",{"date":127,"type":43},"2025-08-12",{"date":129,"type":20},"2026-03",{"name":131,"class":81},"Outliers, Inc.",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":58,"sex":16,"minAge":140,"maxAge":113,"enrollmentInfo":141,"targetDuration":4,"studyType":21,"phases":143,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100569566","phase-4-modulation-of-the-brain-fog-scale-by-eicosapentaenoic-acid-monoglycerides-mag-epa-100569566","NCT06695910","Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).","Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA) in Volunteers Who Reported Suffering From Haze or Mental Fatigue on a Regular Basis. Exploratory Study (NBF-MG01).","NBF-MG01","Inclusion Criteria:\n\n1. Participant between 19 and 55 years of age.\n2. Participant who reports having mental fatigue and\u002For frequent memory loss and\u002For difficulty concentrating and\u002For inattention, confusion and\u002For a feeling of decreased cognitive acuity for at least 28 days at the time of selection.\n3. Participant who obtains a mean score on the BFS screening questionnaires (BFS1 and BFS2) total of at least 30 and\u002FOR who obtains the following minimum score on at least one of the three factors: Factor 1 of at least 15 and\u002For Factor 2 of at least 15 and\u002For Factor 3 of at least 12.\n4. Available for the entire duration of the study and willing to participate based on the information provided in the ICF duly read and signed by the latter.\n5. Absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements, ability to cooperate adequately, ability to understand and observe the instructions of the research staff.\n6. Participant having no difficulty in swallowing tablets, capsules or gelcaps.\n\nExclusion Criteria:\n\n1. Known allergy or intolerance to fish or history of allergic reactions attributable to fish, or to a compound similar to fish oil.\n2. Participant who has used omega-3 supplements in the 30 days preceding day 1 of the study.\n3. Pregnant or breastfeeding woman as declared by the latter.\n4. Presence of dependence on drugs of abuse or alcohol (˃ 3 units of alcohol per day, acute or chronic excessive consumption).\n5. Participant included in another clinical study and who is receiving an investigational product or other research treatment.","19 Years",{"count":142,"type":20},48,[144],"PHASE4","A growing body of studies shows that omega-3s act directly in molecular signaling pathways that reduce inflammation and are thought to have a positive effect on cognitive health. Brain fog is a term that has been popularized in the medical world in the wake of the COVID-19 pandemic. A significant proportion of patients with long COVID reported having cognitive sequelae that were like fogginess. It is defined as a cognitive impairment with characteristic symptoms including problems with concentration, attention and memory, confusion, difficulty understanding what others are saying, reduced mental acuity and mental fatigue. These are episodes of reduced cognitive capacity that are not representative of the person's normal state. This condition can be caused by various factors such as stress, lack of sleep, overwork, depression, hormonal changes due to pregnancy or menopause in women, head injuries, migraine, certain diseases or viral infections, certain medications as well as substance abuse (alcohol and\u002For street drugs). In this study, we want to test whether omega-3 monoglycerides (MAG-EPA) can modulate the cognitive health of people with brain fog.",[31,147],"Cognitive Health","2025-12-04",{"date":150,"type":43},"2025-12-11",{"date":152,"type":43},"2024-11-06",{"date":154,"type":20},"2027-07-01",{"name":156,"class":81},"Samuel Fortin",2,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":21,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":157},"100604798","transcranial-ultrasound-stimulation-for-cognitive-function-modulation-in-patients-with-post-covid-19-brain-fog-100604798","NCT07154199","Transcranial Ultrasound Stimulation for Cognitive Function Modulation in Patients With Post COVID-19 Brain Fog","Inclusion Criteria:\n\n* Patients should have a history of COVID-19 infection (positive test results for either polymerase chain reaction or rapid antigen test) and report persistent brain fog (BF) symptoms at least 4 weeks after recovering from acute COVID-19.\n\nExclusion Criteria:\n\n* 1\\. Presence of any symptoms of cognitive impairment or other neurological symptoms prior to COVID-19 infection;\n* 2\\. Structural MRI revealing significant intracranial lesions or structural abnormalities;\n* 3\\. Development of severe neurological complications after COVID-19 infection, including delirium, cerebrovascular diseases, encephalitis, and epilepsy;\n* 4\\. Other disorders that may cause cognitive impairment, including Dementia, Schizophrenia spectrum disorders, stroke, Alzheimer's disease, and Parkinson's disease.","75 Years",{"count":166,"type":20},40,[23],"This study aims to investigate whether a specific brain region mediates the cognitive deficit in long COVID brain fog, and whether targeted modulation of this region can improve cognition.\n\nIn observational study, the objective was to identify potential intervention targets for patients with long COVID brain fog. A total of 120 patients with long COVID were enrolled. Brain fog (BF) severity was quantified using the Brain Fog Assessment (BFA). Participants completed a continuous random-dot motion (cRDM) task during 128-channel electroencephalography (EEG) and underwent structural MRI and standardized neuropsychological testing.\n\nIn interventional study, 40 participants with persistent BF symptoms were enrolled for transcranial ultrasound stimulation (TUS). On Day 1, participants completed the BFA and provided demographic data, then performed the baseline cRDM task; 20 minutes later, structural MRI and baseline resting-state MRI were acquired. On Day 2, participants received 60 seconds of TUS (active or sham) according to randomized allocation. Twenty minutes post-stimulation, an 8-minute resting-state MRI scan was obtained, followed immediately by the follow-up cRDM task.",[97,31,93,170],"Transcranial Ultrasound Stimulation","2025-09-02",{"date":173,"type":43},"2025-09-04",{"date":175,"type":43},"2023-01-06",{"date":105,"type":20},{"name":178,"class":50},"Xuanwu Hospital, Beijing"]